

VPA10481/002/001

EKYFLOGYL 1.8mg/ml + 8.7mg/ml GEL FOR HORSES

Variation	Summary	Date
Vet - B44 a)	VNRA - Vet - B44 a) - - Vet - B44 a) - Submission of a Ph. Eur. CEP for:— active substance;— starting material, reagent or intermediate used in the manufacturing process of the active substance;— excipient - Updated certificate	22/12/25
Vet - G.I.18	VRA-S - Vet - G.I.18 - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004 - G.I.18 Safety, Efficacy, Pharmacovigilance changes - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004	16/02/24
C.I.9.c	IA - C.I.9.c - c) Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system (e.g. change of the major storage/archiving location, administrative changes) - C.I.9.c - SAFETY, EFFICACY, PHARMACOVIGILANCE CHANGES - HUMAN AND VETERINARY MEDICINAL PRODUCTS - Change(s) to an existing pharmacovigilance system as described in the detailed description of the pharmacovigilance system (DDPS) - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system (e.g. change of the major storage/archiving location, administrative changes)	23/12/22
A.1	IAin - A.1 - A.1 Change in the name and/or address of the marketing authorisation holder - A.1 - ADMINISTRATIVE CHANGES - Change in the name and/or address of the marketing authorisation holder	23/12/22
Vet - B26 a)	VNRA - Vet - B26 a) - a) Up to 10-fold increase compared to the originally approved batch size of an immediate release oral pharmaceutical forms or of a non-sterile liquid based pharmaceutical form - B26 a) Changes to the quality part of the dossier: Change in the batch size (including batch size ranges) of the finished product: — up to 10-fold increase compared to the originally approved batch size of an immediate release oral pharmaceutical forms or of a non-sterile liquid based pharmaceutical form	22/09/22